Prognosis of oesophageal and gastro-oesophageal junctional cancer
View Patent ↗The present invention relates to a method of aiding in the prognosis of a subject with oesophageal and/or gastro-oesophageal junctional (GOJ) adenocarcinoma, the method comprising the steps of: (a) providing a sample from the subject, (b) determining the expression level of biomarkers TRIM44 and SIRT2 in said sample, and either (i) determining the expression level of biomarker PAPPS2 in said sample; or (ii) determining the expression level of biomarkers WT1 and EGFR in said sample; (c) comparing the expression level of each of said biomarkers to a corresponding reference standard, (d) determining the biomarkers of (b) whose expression is dysregulated compared to the reference standard, (e) inferring from the dysregulated biomarkers identified in (d) the prognosis of 5-year survival, wherein the greater the number of said biomarkers which are dysregulated, the greater the reduction in prognosis of 5-year survival. The invention also relates to kits, uses and devices.
1. An in vitro method for identifying a human subject having a poor prognosis of 5-year survival of oesophageal and/or gastro-oesophageal junctional (GOJ) adenocarcinoma, the method comprising the steps of:
(a) obtaining a tumor tissue sample from said human subject;
(b) determining by RT-PCR assay the quantitative expression level of a combination of target genes in said in vitro tumor tissue sample obtained in step (a), wherein the combination of target genes consists of TRIM44, SIRT2, EGFR, and WT1, and the RT-PCR assay utilizes at least one primer selected from the group consisting of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, and SEQ ID NO.8;
(c) comparing the expression level of each target gene in said combination determined in step (b) with a reference standard for each target gene;
(d) detecting an at least 1.3 fold higher level of expression of TRIM44, SIRT2 or EGFR, or an at least 1.3 fold lower level of expression of WT1 as compared with said reference standards in step (c),
wherein detecting an at least 1.3 fold higher level of expression of at least one of TRIM44, SIRT2 and EGFR as compared with said reference standards indicates a dysregulated TRIM44, SIRT2 and/or EGFR target gene, and an at least 1.3 fold lower level of expression of WT1 as compared with said reference standard indicates a dysregulated WT1 target gene; and
(e) identifying said human subject as having a poor prognosis of 5-year survival of oesophageal and/or GOJ adenocarcinoma based on the dysregulation of at least two of said target genes in said combination consisting of TRIM44, SIRT2, EGFR, and WT1 as detected in step (d).
2. The in vitro method according to claim 1 , wherein said reference standard is selected from the group consisting of:
an expression level analysis of a tissue sample from at least one subject that does not have oesophageal and/or GOJ adenocarcinoma that is measured in parallel with the tumor tissue sample for expression of said combination of target genes,
an expression level value for said combination of target genes previously measured from at least one sample taken from at least one subject that does not have oesophageal and/or GOJ adenocarcinoma, and
a set of expression level values for said combination of target genes measured over time as a mean.
3. An in vitro assay for identifying a patient with poor prognosis of 5-year survival of oesophageal and/or gastro-oesophageal junctional (GOJ) adenocarcinoma comprising:
(a) conducting RT-PCR with genetic material from a sample of tumor tissue obtained from said patient to determine a quantitative expression level of a prognostic biomarker panel consisting of biomarkers TRIM44, SIRT2, EGFR, and WT1, wherein the RT-PCR assay utilizes at least one primer selected from the group consisting of SEQ ID NO. 1, SEQ ID NO.2, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, and SEQ ID NO.8;
(b) comparing the expression level of said prognostic panel of biomarkers with the expression level of a reference standard of said panel of biomarkers;
(c) determining an at least 1.3 fold increase in expression level of at least one of TRIM44, SIRT2, and EGFR as compared with said reference standard, optionally determining an at least 1.3 fold decrease in expression level of WT1 as compared with said corresponding reference standard, wherein said determining indicates dysregulation of said biomarker;
wherein dysregulation of biomarkers TRIM44, SIRT2, EGFR, and/or WT1 identifies the patient as having poor prognosis of 5-year survival of oesophageal and/or GOJ adenocarcinoma; and
(d) treating the patient for oesophageal and/or GOJ adenocarcinoma with poor prognosis of 5-year survival of oesophageal and/or GOJ adenocarcinoma.
4. The in vitro method according to claim 3 , wherein said reference standard is selected from the group consisting of:
an expression level analysis of genetic material from a sample obtained from at least one subject that does not have oesophageal and/or GOJ adenocarcinoma that is measured in parallel with the tumor tissue sample for expression of said combination of target genes,
an expression level value for said combination of target genes previously measured in the genetic material from at least one sample taken from at least one subject that does not have oesophageal and/or GOJ adenocarcinoma, and
a set of expression level values for said combination of target genes measured over time as a mean.